Literature DB >> 20595817

Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.

Manujendra N Saha1, Hua Jiang, Hong Chang.   

Abstract

Multiple myeloma (MM) is an incurable plasma cell malignancy in which p53 is rarely mutated. Thus, activation of the p53 pathway by a small molecule inhibitor of the p53-MDM2 interaction, nutlin, in MM cells retaining wild type p53 is an attractive therapeutic strategy. Recently we reported that nutlin plus velcade (a proteasome inhibitor) displayed a synergistic response in MM. However, the mechanism of the p53-mediated apoptosis in MM has not been fully understood. Our data show that nutlin-induced apoptosis correlated with reduction in cell viability, upregulation of p53, p21 and MDM2 protein levels with a simultaneous increase in pro-apoptotic targets PUMA, Bax and Bak and downregulation of anti-apoptotic targets Bcl2 and survivin and activation of caspase in MM cells harboring wild type p53. Nutlin-induced apoptosis was inhibited when activation of caspase was blocked by the caspase inhibitor. Nutlin caused mitochondrial translocation of p53 where it binds with Bcl2, leading to cytochrome C release. Moreover, blocking the transcriptional arm of p53 by the p53-specific transcriptional inhibitor, pifithrin-α, not only inhibited nutlin-induced upregulation of p53-transcriptional targets but also augmented apoptosis in MM cells, suggesting an association of transcription-independent pathway of apoptosis. However, inhibitor of mitochondrial translocation of p53, PFT-μ, did not prevent nutlin-induced apoptosis, suggesting that the p53 transcription-dependent pathway was also operational in nutlin-induced apoptosis in MM. Our study provides the evidence that nutlin-induced apoptosis in MM cells is mediated by transcription-dependent and -independent pathways and supports further clinical evaluation of nutlin as a novel therapeutic agent in MM.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20595817      PMCID: PMC3040946          DOI: 10.4161/cbt.10.6.12535

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  52 in total

Review 1.  Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway.

Authors:  Sara B Cullinan; J Alan Diehl
Journal:  Int J Biochem Cell Biol       Date:  2005-10-28       Impact factor: 5.085

2.  Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma.

Authors:  Thorsten Stühmer; Manik Chatterjee; Martin Hildebrandt; Pia Herrmann; Hella Gollasch; Christian Gerecke; Sebastian Theurich; Luisa Cigliano; Rudolf A Manz; Peter T Daniel; Kurt Bommert; Lyubomir T Vassilev; Ralf C Bargou
Journal:  Blood       Date:  2005-08-04       Impact factor: 22.113

Review 3.  Multiple roles of the tumor suppressor p53.

Authors:  Jill Bargonetti; James J Manfredi
Journal:  Curr Opin Oncol       Date:  2002-01       Impact factor: 3.645

4.  Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation.

Authors:  W J M Mackus; A P Kater; A Grummels; L M Evers; B Hooijbrink; M H H Kramer; J E Castro; T J Kipps; R A W van Lier; M H J van Oers; E Eldering
Journal:  Leukemia       Date:  2005-03       Impact factor: 11.528

Review 5.  Functions of the MDM2 oncoprotein.

Authors:  D A Freedman; L Wu; A J Levine
Journal:  Cell Mol Life Sci       Date:  1999-01       Impact factor: 9.261

Review 6.  Pharmacological activation of the p53 pathway in haematological malignancies.

Authors:  Manujendra N Saha; Johann Micallef; Lugui Qiu; Hong Chang
Journal:  J Clin Pathol       Date:  2009-12-02       Impact factor: 3.411

7.  Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.

Authors:  Melissa G Ooi; Patrick J Hayden; Vassiliki Kotoula; Douglas W McMillin; Elpida Charalambous; Emily Daskalaki; Noopur S Raje; Nikhil C Munshi; Dharminder Chauhan; Teru Hideshima; Leutz Buon; Martin Clynes; Peter O'Gorman; Paul G Richardson; Constantine S Mitsiades; Kenneth C Anderson; Nicholas Mitsiades
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

Review 8.  Targeting the MDM2-p53 interaction for cancer therapy.

Authors:  Sanjeev Shangary; Shaomeng Wang
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

9.  Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.

Authors:  Kensuke Kojima; Marina Konopleva; Teresa McQueen; Susan O'Brien; William Plunkett; Michael Andreeff
Journal:  Blood       Date:  2006-03-16       Impact factor: 22.113

10.  The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53.

Authors:  E Drakos; V Atsaves; E Schlette; J Li; I Papanastasi; G Z Rassidakis; L J Medeiros
Journal:  Leukemia       Date:  2009-09-10       Impact factor: 11.528

View more
  26 in total

1.  Nutlin's two roads toward apoptosis.

Authors:  Qi Zhang; Hua Lu
Journal:  Cancer Biol Ther       Date:  2010-09-24       Impact factor: 4.742

2.  Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.

Authors:  Merav Leiba; Jana Jakubikova; Steffen Klippel; Constantine S Mitsiades; Teru Hideshima; Yu-Tzu Tai; Adi Leiba; Mark Pines; Paul G Richardson; Arnon Nagler; Kenneth C Anderson
Journal:  Br J Haematol       Date:  2012-04-26       Impact factor: 6.998

3.  The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery.

Authors:  Biyin Cao; Xinliang Mao
Journal:  Am J Blood Res       Date:  2011-05-25

4.  Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity.

Authors:  Kimo C Stine; Elizabeth C Wahl; Lichu Liu; Robert A Skinner; Jaclyn VanderSchilden; Robert C Bunn; Corey O Montgomery; James Aronson; David L Becton; Richard W Nicholas; Christopher J Swearingen; Larry J Suva; Charles K Lumpkin
Journal:  J Orthop Res       Date:  2016-02-26       Impact factor: 3.494

Review 5.  Pharmacologic activation of p53 by small-molecule MDM2 antagonists.

Authors:  Hong Shen; Carl G Maki
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 6.  Drugging the p53 pathway: understanding the route to clinical efficacy.

Authors:  Kian Hoe Khoo; Khoo Kian Hoe; Chandra S Verma; David P Lane
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

Review 7.  Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.

Authors:  Tiffany Devine; Mu-Shui Dai
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

8.  Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.

Authors:  Jian-Jun Zhao; Zhang-Bo Chu; Yu Hu; Jianhong Lin; Zhongqiu Wang; Meng Jiang; Ming Chen; Xujun Wang; Yue Kang; Yangsheng Zhou; Triona Ni Chonghaile; Melanie E Johncilla; Yu-Tzu Tai; Jin Q Cheng; Antony Letai; Nikhil C Munshi; Kenneth C Anderson; Ruben D Carrasco
Journal:  Cancer Res       Date:  2015-08-06       Impact factor: 12.701

9.  p53 haploinsufficiency and functional abnormalities in multiple myeloma.

Authors:  P J Teoh; T H Chung; S Sebastian; S N Choo; J Yan; S B Ng; R Fonseca; W J Chng
Journal:  Leukemia       Date:  2014-03-14       Impact factor: 11.528

10.  c-Abl mediates angiotensin II-induced apoptosis in podocytes.

Authors:  Xinghua Chen; Zhilong Ren; Wei Liang; Dongqing Zha; Yipeng Liu; Cheng Chen; Pravin C Singhal; Guohua Ding
Journal:  J Mol Histol       Date:  2013-03-21       Impact factor: 2.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.